CDKN2A and cancer: In more detail, 5-year OS and DFS were 78.8% and 85.9%, respectively, in patients with HPVDNA+/p16+ TSCC/BOTSCC and 37.9% and 57.5%, respectively, in patients with HPVDNA−/p16− cancer.